A ONCE-WEEKLY GLP-1 RA
Indications and clinical use:
Ozempic® (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with:
Not a substitute for insulin. Not for use in type 1 diabetes or for the treatment of diabetic ketoacidosis. Ozempic® is not indicated for use in pediatric patients.
Most serious warnings and precautions:
Risk of thyroid C-cell tumours: In both genders of rats and mice, semaglutide causes treatment-dependent thyroid C-cell tumours. Patients should be counselled regarding the risk and symptoms of thyroid tumours.
Other relevant warnings and precautions:
For more information:
Please consult the Product Monograph at OzempicPM-E.ca for more information relating to adverse reactions, drug interactions, and dosing information, which have not been discussed in this advertisement.
The Product Monograph is also available by calling us at 1-800-465-4334.
Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:
Novo Nordisk Canada Inc.
101-2476 Argentia Road
Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST
Main fax number:
Toll-free fax number: